Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

PDE4 inhibitor mitigates activated CD8+ T cells through NF-κB signaling in Behçet's syndrome.

Created on 13 Oct 2026

Authors

Alexandre Le Joncour, Paul Régnier, Anna Maciejewski-Duval, Erwan Charles, Cloé Comarmond, Stéphane Barete, Matheus Vieira, Pierre Fouret, Alexandre Belot, Sébastien Viel, Michelle Rosenzwajg, David Klatzmann, Patrice Cacoub, David Saadoun

Published in

Frontiers in immunology. Volume 17. Pages 1834685. Epub Jun 29, 2026.

Abstract

Behçet's disease (BD) is a systemic vasculitis with inflammatory lesions mediated by cytotoxic T cells and neutrophils. Here, we explore the critical involvement of NF-κB signaling pathway in proinflammatory CD8+ T cells differentiation and disease progress of BD patients.
We performed microarray gene expression analyses, flow cytometry, immunophenotyping, immunohistochemistry and functional assessments of CD8+ T cells from BD patients and HD.
Transcriptionally, among the 6,595 up-regulated genes in CD8+ T cells of BD vs HD, we highlighted a great enrichment for pathways linked to NF-κB and TLR signaling (i.e. NFKB1, RELB, REL, TLR1, IRF4). Phenotypically, CD8+ T cells from BD had a higher expression of phosphorylated NF-κB (pNF-κB, 4.4 ± 0.9 vs. 1.8 ± 0.2 in MFI, p = 0.001), were more activated (higher CD11c, CD11b, CD25 and TNF-α, IFN-γ expression) and exhibited more expression of Perforin and Granzyme B (33% ± 9 vs. 9 ± 5, p = 0.009, 47% ± 8 vs.21% ± 6, p = 0.02, respectively) as compared to HD. Phosphodiesterase-4 (PDE4), an immune cell enzyme that activate the NF-κB pathway was up-regulated in blood and skin lesions of BD. In vitro and in vivo inhibition of PDE4 strongly inhibited CD8+ T cell activation, cytokine secretion, cytotoxicity and proliferation.
We highlighted that activated CD8+ T cells through NF-κB signaling pathway are instrumental in BD.

PMID:
42445175
Bibliographic data and abstract were imported from PubMed on 13 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 14
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement